HER-2 Positive Breast Cancer Clinical Trial Using Trastuzumab

- The folks at National Institute for Cancer Research, Italy are studying the effects of Trastuzumab on HER-2 Positive Breast Cancer in females ages 18 years and older. This clinical trial is slated to start March 2011.

+390105600387
Lucia Del Mastro, MD
Overall Study Contact Info
StatusName Contact Phone
RecruitingLucia Del Mastro, MDlucia.delmastro@istge.it+390105600387

This study is officially titled, "Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.."

Locations

Istituto Nazionale per La Ricerca sul Cancro (IST)

Genoa, Ge - Recruiting

Ospedale S. Maria della Misericordia - Oncologia Medica

Perugia, PG - Not yet recruiting

Fondazione del Piemonte per l'Oncologia - IRCC di Candiolo

Candiolo, TO - Not yet recruiting

Ospedale Mauriziano Umberto I - Ginecologia Oncologica

Torino, TO - Not yet recruiting

Ospedale Ostetrico Ginecologico S. Anna Di Torino - Oncologia Medica

Torino, To - Not yet recruiting

Ospedale Sacro Cuore - Don Calabria - Oncologia Medica

Negrar, VR - Not yet recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.